February 2, 2015 / 6:16 AM / 3 years ago

BRIEF-FDA grants therapy designation for Genentech cancer treatment

Feb 2 (Reuters) - Roche Holding AG

* FDA grants breakthrough therapy designation for genentech's investigational cancer immunotherapy mpdl3280a (anti-pdl1) in non-small cell lung cancer

* Ongoing pivotal studies of mpdl3280a include lung and bladder cancer, and we plan to initiate phase iii studies in additional tumor types this year Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below